A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)
Status:
Completed
Trial end date:
2014-02-27
Target enrollment:
Participant gender:
Summary
The main objectives of the study were to evaluate the safety and tolerability of
afamelanotide by measuring treatment emergent adverse events (AEs) and to determine whether
afamelanotide can improve the quality of life of EPP patients.